Guidance, NICE advice and quality standards in development

Showing 331 to 340 of 383

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Suspected sepsis: recognition, diagnosis and early management	NICE guideline	13 August 2025
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]	Technology appraisal guidance	19 June 2024
Talacotuzumab for untreated acute myeloid leukaemia [ID1262]	Technology appraisal guidance	TBC
Talazoparib with enzalutamide for untreated hormone-relapsed metastatic prostate cancer [ID4004]	Technology appraisal guidance	TBC
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]	Technology appraisal guidance	11 December 2024
Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401	Technology appraisal guidance	TBC
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]	Technology appraisal guidance	TBC
Technologies for the assessment of attention deficit hyperactivity disorder (ADHD)	Diagnostics guidance	TBC
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]	Technology appraisal guidance	14 August 2024
Telisotuzumab vedotin for treating c-MET overexpressed, EGFR wild-type, non-squamous advanced non-small-cell lung cancer after 1 or more systemic treatments [ID6253]	Technology appraisal guidance	TBC